

s (R P K H P OR ARG PRO LYS HIS PRO) and (CASEIN OR S1 (A) CASEIN?)

L12 16 FILE USPATFULL  
L13 1 FILE AGRICOLA  
L14 1 FILE CABA  
L15 1 FILE CAPLUS  
L16 1 FILE SCISEARCH  
L17 1 FILE BIOSIS  
L18 1 FILE MEDLINE  
L19 1 FILE USPAT2

TOTAL FOR ALL FILES

L20 23 (R P K H P OR ARG PRO LYS HIS PRO) AND (CASEIN OR S1 (A) CASEIN?)  
)

=> Dup rem l20

PROCESSING COMPLETED FOR L20

L21 17 DUP REM L20 (6 DUPLICATES REMOVED)

=> D l21 1-17 ibib abs

L21 ANSWER 1 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:324008 USPATFULL

TITLE: Methods and compositions involving endopeptidases PepO2  
and PepO3

INVENTOR(S): Steele, James L., Cross Plains, WI, UNITED STATES  
Broadbent, Jeffrey R., Smithfield, UT, UNITED STATES  
Sridhar, Vidya R., Portland, OR, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005281914	A1	20051222
APPLICATION INFO.:	US 2004-873427	A1	20040621 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-480536P	20030620 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1-84	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	3867	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns the methods and compositions involving endopeptidase enzymes, especially PepO2 and PepO3 from *L. helveticus*, and their use in reducing bitterness by cleaving bitter peptides. In particular embodiments of the invention, these methods and compositions apply to the cheesemaking process. The invention also concerns the use of PepO2 and/or PepO3 polypeptides in the treatment or prevention of celiac sprue or as a food additive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 2 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:286455 USPATFULL

TITLE: Enzyme treatment of foodstuffs for Celiac Sprue

INVENTOR(S): Shan, Lu, Stanford, CA, UNITED STATES  
Bethune, Michael, Stanford, CA, UNITED STATES  
Khosla, Chaitan, Palo Alto, CA, UNITED STATES  
Gass, Jonathan, Stanford, CA, UNITED STATES  
Pyle, Gail G., Stanford, CA, UNITED STATES  
Gray, Gary M., Stanford, CA, UNITED STATES  
Isaacs, Indu, Andover, MA, UNITED STATES  
Strohmeier, Gregg, Andover, MA, UNITED STATES  
PATENT ASSIGNEE(S): The Board of Trustees of the Leland Stanford Junior  
University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005249719	A1	20051110
APPLICATION INFO.:	US 2004-969314	A1	20041019 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-367405, filed on 14 Feb 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-357238P	20020214 (60)
	US 2002-380761P	20020514 (60)
	US 2002-392782P	20020628 (60)
	US 2002-422933P	20021031 (60)
	US 2002-428033P	20021120 (60)
	US 2002-435881P	20021220 (60)
	US 2004-565668P	20040426 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 1900 UNIVERSITY AVENUE, SUITE 200, EAST PALO ALTO, CA, 94303, US	
NUMBER OF CLAIMS:	36	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	3285	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 3 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 2005:196192 USPATFULL  
 TITLE: Identification of etiology of autism  
 INVENTOR(S): Vojdani, Aristo, Los Angeles, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005170333	A1	20050804
APPLICATION INFO.:	US 2004-770712	A1	20040203 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614, US		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	22 Drawing Page(s)		
LINE COUNT:	3959		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein is a method for following up a prognosis of children with autism before and after treatment with different modalities administered by their clinicians, confirming the involvement of infectious agents, dietary proteins, and toxic chemicals in development of autism. The method utilizes detection of increased amounts of antibodies against an antigen based on infectious agent, toxic chemicals, or dietary proteins. Another method utilizes detection of antibodies to a self-tissue or peptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 4 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 2005:189388 USPATFULL  
 TITLE: Molecular scaffolds for kinase ligand development  
 INVENTOR(S): Artis, Dean R., Kensington, CA, UNITED STATES  
 Bremer, Ryan E., Oakland, CA, UNITED STATES  
 Gillette, Samuel J., Oakland, CA, UNITED STATES  
 Hurt, Clarence R., San Ramon, CA, UNITED STATES  
 Ibrahim, Prabha L., Mountain View, CA, UNITED STATES  
 Zuckerman, Rebecca L., Alameda, CA, UNITED STATES

PATENT ASSIGNEE(S): Plexxikon, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005164300	A1	20050728
APPLICATION INFO.:	US 2004-941635	A1	20040915 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-503277P	20030915 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278, US	
NUMBER OF CLAIMS:	74	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	19944	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Molecular scaffolds for compounds active on protein kinases are described, along with methods for using such scaffolds for kinase ligand development. The use of kinase structural information, exemplified with PIM-1 crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate particular kinases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 5 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:81466 USPATFULL

TITLE: DNA polymerase compositions for quantitative PCR and methods thereof

INVENTOR(S): Sorge, Joseph A., Wilson, WY, UNITED STATES  
Mueller, Reinhold Dietrich, San Diego, CA, UNITED STATES  
Padmabandu, Gothami, San Diego, CA, UNITED STATES  
Roelofs, Nick, San Diego, CA, UNITED STATES  
Hogrefe, Holly H., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Stratagene (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005069908	A1	20050331
APPLICATION INFO.:	US 2003-734563	A1	20031212 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-408601, filed on 7 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2002-298680, filed on 18 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-280962, filed on 25 Oct 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS / STR, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	62 Drawing Page(s)		
LINE COUNT:	7978		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the generation and characterization of Archaeal DNA polymerase mutants with deficient 3'-5' exonuclease activity and reduced base analog detection activity. The invention further provides for Archaeal DNA polymerase mutants with deficient 3'-5' exonuclease activity and reduced base analog detection activity containing additional mutations that modulate other DNA polymerase activities including DNA polymerization or reverse transcriptase activity. The invention also discloses methods and applications of DNA polymerases with deficient 3'-5' exonuclease activity and reduced base analog detection activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 6 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2005:38013 USPATFULL

TITLE: Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization

INVENTOR(S): Gerritsen, Mary E., San Mateo, CA, UNITED STATES  
Goddard, Audrey, San Francisco, CA, UNITED STATES  
Grimaldi, J. Christopher, San Francisco, CA, UNITED STATES

PATENT ASSIGNEE(S): Mehraban, Fuad, Trumbull, CT, UNITED STATES  
Genentech, Inc., South San Francisco, CA (U.S. corporation)  
Curagen Corporation, New Haven, CT (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005032693	A1	20050210
APPLICATION INFO.:	US 2004-811080	A1	20040326 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-684458, filed on 5 Oct 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-158587P	19991007 (60)
	US 1999-162611P	19991028 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9418	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to novel polypeptides critical for angiogenesis and vascularization, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Compositions and methods are disclosed for stimulating or inhibiting angiogenesis and/or neo- or cardio-vascularization in mammals, including humans. Pharmaceutical compositions are based on polypeptides or antagonists thereto that have been identified for one or more of these uses. Disorders that can be diagnosed, prevented, or treated by the compositions herein include trauma such as wounds; various cancers, and disorders of the vessels including atherosclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 7 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:280309 USPATFULL

TITLE: Methods for modulating proteins not previously known as proteases

INVENTOR(S): Day, Anthony G., San Francisco, CA, UNITED STATES  
Estell, David A., San Mateo, CA, UNITED STATES  
Lyons, Eric H., El Cerrito, CA, UNITED STATES  
Yao, Jian, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004219609	A1	20041104
APPLICATION INFO.:	US 2003-618281	A1	20030711 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-395325P	20020712 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: GENENCOR INTERNATIONAL, INC., 925 PAGE MILL ROAD, PALO ALTO, CA, 94304-1013  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
LINE COUNT: 10564

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the proteins not previously identified as proteases; the use of those peptides in screening for compounds that modulate protease activity; treating individuals in need of treatment with the compounds or proteases; and in methods for diagnosing a disease or disorder associated with a protease of the instant invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 8 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:215964 USPATFULL  
TITLE: **Casein** derived peptides and uses thereof  
INVENTOR(S): Sidelman, Zvi, Tel Aviv, ISRAEL  
PATENT ASSIGNEE(S): Chay 13 Medical Research Group N.V. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004167073	A1	20040826
APPLICATION INFO.:	US 2004-788400	A1	20040301 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IL 2002-200720	20020829
	IL 2001-100198	20010301
	IL 2000-134830	20000301
	US 2003-467603P	20030505 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: G.E. EHRLICH (1995) LTD., c/o ANTHONY CASTORINA, SUITE 207, 2001 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202  
NUMBER OF CLAIMS: 164  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 21 Drawing Page(s)  
LINE COUNT: 4777

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the  $\alpha$ S1 fraction of milk **casein**. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The **casein**-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases, alone or in combination with other peptides or blood cell stimulating factors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 9 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2004:18779 USPATFULL  
TITLE: Novel proteins and nucleic acids encoding same  
INVENTOR(S): Alsobrook, John P., II, Madison, CT, UNITED STATES  
Spaderna, Steven K., Berlin, CT, UNITED STATES  
Tchernev, Velizar T., Branford, CT, UNITED STATES  
Liu, Xiaohong, Branford, CT, UNITED STATES  
Shenoy, Suresh G., Branford, CT, UNITED STATES  
Spytek, Kimberly A., New Haven, CT, UNITED STATES  
Zerhusen, Bryan D., Branford, CT, UNITED STATES  
Patturajan, Meera, Branford, CT, UNITED STATES  
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES  
Rastelli, Luca, Guilford, CT, UNITED STATES  
Grosse, William M., Branford, CT, UNITED STATES

Szekeres, Edward S., JR., Branford, CT, UNITED STATES  
Lepley, Denise M., Branford, CT, UNITED STATES  
Shen, Lei, Hamden, CT, UNITED STATES  
Burgess, Catherine E., Wethersfield, CT, UNITED STATES  
Shimkets, Richard A., Guilford, CT, UNITED STATES  
Padigaru, Muralidhara, Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014081	A1	20040122
APPLICATION INFO.:	US 2003-369072	A1	20030218 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-174372, filed on 17 Jun 2002, ABANDONED Continuation of Ser. No. US 2001-898994, filed on 3 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215854P	20000703 (60)
	US 2000-215856P	20000703 (60)
	US 2000-215902P	20000703 (60)
	US 2000-216585P	20000707 (60)
	US 2000-216586P	20000707 (60)
	US 2000-216722P	20000707 (60)
	US 2000-218622P	20000717 (60)
	US 2000-218992P	20000717 (60)
	US 2000-221285P	20000727 (60)
	US 2001-268734P	20010214 (60)
	US 2001-274260P	20010308 (60)
	US 2001-279856P	20010329 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: MINTZ, LEVIN, COHN, FERRIS,, GLOVSKY and POPEO, P.C.,  
One Financial Center, Boston, MA, 02111

NUMBER OF CLAIMS: 52  
EXEMPLARY CLAIM: 1  
LINE COUNT: 15688

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 10 OF 17 USPATFULL on STN  
ACCESSION NUMBER: 2004:4537 USPATFULL  
TITLE: Plant lipases  
INVENTOR(S): Cahoon, Edgar B., Wilmington, DE, United States  
PATENT ASSIGNEE(S): E. I. du Pont de Nemours and Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6673988	B1	20040106
APPLICATION INFO.:	US 2000-668097		20000922 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157309P	19991001 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	McElwain, Elizabeth F.	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1,3	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 7 Drawing Page(s)	

LINE COUNT: 2962

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to an isolated nucleic acid fragment encoding a lipase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the lipase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the lipase in a transformed host cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 11 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:26149 USPATFULL

TITLE: Diagnostics and treatments of periodontal disease

INVENTOR(S): Reynolds, Eric Charles, North Balwyn, AUSTRALIA  
Bhogal, Peter Singh, Point Lonsdale, AUSTRALIA  
Slakeski, Nada, East Kew, AUSTRALIA

PATENT ASSIGNEE(S): The University of Melbourne, Parkville, AUSTRALIA  
(non-U.S. corporation)  
Victorian Dairy Industry Authority, Abbotsford,  
AUSTRALIA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6511666	B1	20030128
	WO 9716542		19970509
APPLICATION INFO.:	US 1998-66330		19980915 (9)
	WO 1996-AU673		19961030
			19980915 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	AU 1995-6275	19951030
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Kunz, Gary L.	
ASSISTANT EXAMINER:	Gucker, Stephen	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	2407	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis in particular a multimeric cell associated protein complex comprising the PrtR and PrtK proteins. There is provided a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain. The complex has a molecular weight of greater than about 200 kDa. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 12 OF 17 USPATFULL on STN

DUPLICATE 1

ACCESSION NUMBER: 2002:332607 USPATFULL

TITLE: Phenylalanine-free protein and DNA coding therefor

INVENTOR(S): Carr, Noel Gordon, Warwickshire, UNITED KINGDOM  
Mann, Nicholas Harold, Warwickshire, UNITED KINGDOM

PATENT ASSIGNEE(S): Pharming Holding N. V., NETHERLANDS (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495344	B1	20021217
	US 2002192744	A1	20021219
	WO 9428126		19941208

APPLICATION INFO.: US 1996-545573 19960116 (8)  
 WO 1994-GB1046 19940516  
 19960116 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-10472	19930520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Mitra, Rita	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	1376	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A DNA molecule coding for a food protein, such as ovalbumin or **casein**, modified so that the codons for phenylalanine have been omitted or replaced by codons for one or more other metabolisable amino acids. Also a modified edible protein coded for by such a DNA molecule. Such modified proteins are useful in the nutrition of patients suffering from phenylketonuria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 13 OF 17 USPATFULL on STN  
 ACCESSION NUMBER: 2002:63715 USPATFULL  
 TITLE: Methods of using multivariant IL-3 hematopoiesis fusion protein  
 INVENTOR(S): Bauer, S. Christopher, 4656 Orchard, New Haven, MO, United States 63068  
 Abrams, Mark Allen, 7723 Blackberry Ave., St. Louis, MO, United States 63130  
 Braford-Goldberg, Sarah Ruth, 4111 W. Pine #10, St. Louis, MO, United States 63108  
 Caparon, Maire Helena, 109 Beechwood Ct., Chesterfield, MO, United States 63017  
 Easton, Alan Michael, 2317 Seven Pines Dr. #7, Maryland Heights, MO, United States 63146  
 Klein, Barbara Kure, 12917 Topping Estates, St. Louis, MO, United States 63131  
 McKearn, John P., 18612 Babler Meadows Dr., St. Louis, MO, United States 63038  
 Olins, Peter O., 17507 Summit View, Glencoe, MO, United States 63038  
 Paik, Kumnan, 1021 Alpine Ridge, Ballwin, MO, United States 63021  
 Thomas, John W., 13426 Mason Valley, Town & Country, MO, United States 63131

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6361977	B1	20020326
	WO 9521254		19950810
APPLICATION INFO.:	US 1995-446872		19950606 (8)
	WO 1995-US1185		19950202
			19950606 PCT 371 date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-192325, filed on 4 Feb 1994, now patented, Pat. No. US 6097133		
	Continuation-in-part of Ser. No. WO 1993-US11197, filed on 22 Nov 1993		
	Continuation-in-part of Ser. No. US 1992-981044, filed on 24 Nov 1992		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kunz, Gary L.		
ASSISTANT EXAMINER:	Landsman, Robert S.		
LEGAL REPRESENTATIVE:	Bauer, S. Christopher		
NUMBER OF CLAIMS:	62		



EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)  
LINE COUNT: 13951

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (mteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 14 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:157142 USPATFULL  
TITLE: NANBV diagnostics and vaccines  
INVENTOR(S): Chien, David Y., Alamo, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6150087		20001121
APPLICATION INFO.:	US 1995-444818		19950518 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-403590, filed on 14 Mar 1995 which is a continuation of Ser. No. US 1991-722489, filed on 24 Jun 1991		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Woodward, Michael P.		
LEGAL REPRESENTATIVE:	Robins & Associates, Harbin, Alisa A., Blackburn, Robert P.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	186 Drawing Figure(s); 168 Drawing Page(s)		
LINE COUNT:	22748		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB We have discovered epitopes of the HCV viral proteins which are immunoreactive with immune serum. The epitopes are useful in immunodiagnostic assays and as immunogens.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 15 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:24486 USPATFULL  
TITLE: Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors  
INVENTOR(S): Bauer, S. Christopher, New Haven, MO, United States  
Abrams, Mark Allen, St. Louis, MO, United States  
Braford-Goldberg, Sarah Ruth, Chesterfield, MO, United States  
Caparon, Maire Helena, Chesterfield, MO, United States  
Easton, Alan M., Maryland Heights, MO, United States  
Klein, Barbara Kure, St. Louis, MO, United States  
McKearn, John P., St. Louis, MO, United States  
Olins, Peter O., Superior, MO, United States  
Paik, Kumnan, Wilmette, MO, United States  
Thomas, John W., Town & Country, MO, United States  
PATENT ASSIGNEE(S): G. D. Searle & Company, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6030812		20000229
APPLICATION INFO.:	US 1995-468609		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. WO 1995-US1185, filed on 4 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-192325, filed on 4 Feb 1994 which is a continuation-in-part of Ser. No. WO 1993-US11197, filed on 22 Nov 1993 which is a continuation-in-part of Ser.		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Fitzgerald, David L.  
LEGAL REPRESENTATIVE: Bennett, Dennis A.  
NUMBER OF CLAIMS: 66  
EXEMPLARY CLAIM: 1,26  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)  
LINE COUNT: 11994

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:15311 USPATFULL

TITLE: Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors  
INVENTOR(S): Bauer, S. Christopher, New Haven, MO, United States  
Abrams, Mark Allen, St. Louis, MO, United States  
Braford-Goldberg, Sarah Ruth, Chesterfield, MO, United States  
Caparon, Maire Helen, Chesterfield, MO, United States  
Easton, Alan M., Maryland Heights, MO, United States  
Klein, Barbara Kure, St. Louis, MO, United States  
McKearn, John P., St. Louis, MO, United States  
Olins, Peter O., Superior, CO, United States  
Paik, Kumnan, Wilmette, IL, United States  
Thomas, John W., Town & Country, MO, United States  
PATENT ASSIGNEE(S): G. D. Searle & Company, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6022535		20000208
APPLICATION INFO.:	US 1995-469318		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. WO 1994-US9501185, filed on 4 Feb 1994 which is a continuation-in-part of Ser. No. US 1994-192325, filed on 4 Feb 1994 which is a continuation-in-part of Ser. No. WO 1993-US11197, filed on 22 Nov 1993 which is a continuation-in-part of Ser. No. US 1995-411795, filed on 6 Apr 1995, now patented, Pat. No. US 5604116		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Fitzgerald, David L.  
LEGAL REPRESENTATIVE: Bennett, Dennis A.  
NUMBER OF CLAIMS: 62  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)  
LINE COUNT: 14119

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 17 OF 17 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved.  
(2006) on STN DUPLICATE 2

ACCESSION NUMBER: 2001:61956 AGRICOLA  
DOCUMENT NUMBER: IND23218252

TITLE: Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese.  
AUTHOR(S): Saito, T.; Nakamura, T.; Kitazawa, H.; Kawai, Y.; Itoh, T.  
SOURCE: Journal of dairy science, July 2000. Vol. 83, No. 7. p. 1434-1440  
Publisher: Savoy, Ill. : American Dairy Science Association.  
CODEN: JDSCAE; ISSN: 0022-0302  
NOTE: Includes references  
PUB. COUNTRY: Illinois; United States  
DOCUMENT TYPE: Article  
FILE SEGMENT: U.S. Imprints not USDA, Experiment or Extension  
LANGUAGE: English

AB Seven kinds of ripened cheeses (8-mo-aged and 24-mo-aged Gouda, Emmental, Blue, Camembert, Edam, and Havarti) were homogenized with distilled water, and water-soluble peptides were prepared by C-18 hydrophobic chromatography. The inhibitory activity to angiotensin I-converting enzyme and decrease in the systolic blood pressure in spontaneously hypertensive rats were measured before and after oral administration of each peptide sample. The strongest depressive effect in the systolic blood pressure (-24.7 mm Hg) and intensive inhibitory activity to angiotensin I-converting enzyme (75.7%) were detected in the peptides from 8-mo-aged Gouda cheese. Four peptides were isolated by HPLC with reverse-phase and gel filtration modes. Their chemical structures and origins, clarified by combination analyses of protein sequencing, amino acid composition, and mass spectrometry, were as follows: peptide A, **Arg-Pro-Lys-His-Pro-Ile-Lys-His-Gln** [alpha(s1)-casein (CN), B-8P; f 1-9]; peptide B, **Arg-Pro-Lys-His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln** (alpha(s1)-CN, B-8P; f 1-13); peptide F, **Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn** (beta-CN, A2-5P; f 60-68); and peptide G, **Met-Pro-Phe-Pro-Lys-Tyr-Pro-Val-Gln-Pro-Phe** (beta-CN, A2-5P; f 109-119). Peptides A and F, which were chemically synthesized, showed potent angiotensin I-converting enzyme inhibitory activity with little antihypertensive effects.

=>

FILE 'HOME' ENTERED AT 20:29:00 ON 13 FEB 2006

=> index chemistry bioscience medicine  
FILE 'ENCOMPLIT2' ACCESS NOT AUTHORIZED  
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUALINE, AQUIRE, BABS, BIOTECHNO,  
CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CERAB, CIN, COMPENDEX, CONFSCI,  
COPPERLIT, CORROSION, DISSABS, ENCOMPLIT, FEDRIP, GENBANK, INSPEC,  
INSPHYS, INVESTEXT, IPA, JICST-EPLUS, ...' ENTERED AT 20:29:27 ON 13 FEB 2006

95 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view  
search error messages that display as 0\* with SET DETAIL OFF.

=> s (rpkhp or Arg Pro Lys his Pro) (P) ( casein or S1 casein?)

- 1 FILE AGRICOLA
- 0\* FILE ALUMINIUM
- 0\* FILE APOLLIT
- 0\* FILE AQUALINE
- 0\* FILE BABS
- 0\* FILE BIOTECHNO
- 1 FILE CABA
- 0\* FILE CAOLD
- 1 FILE CAPLUS
- 0\* FILE CBNB
- 0\* FILE CEABA-VTB
- 0\* FILE CIN
- 0\* FILE COMPENDEX
- 0\* FILE COPPERLIT
- 0\* FILE CORROSION
- 0\* FILE ENCOMPLIT
- 0\* FILE FEDRIP
- 0\* FILE INSPEC
- 0\* FILE INSPHYS
- 0\* FILE KOSMET
- 0\* FILE METADEX

30 FILES SEARCHED...

- 0\* FILE NTIS
- 1\* FILE PASCAL
- 0\* FILE RAPRA
- 1 FILE SCISEARCH
- 0\* FILE WATER
- 0\* FILE WELDASEARCH
- 0\* FILE WSCA
- 0\* FILE ADISNEWS
- 0\* FILE ANTE
- 0\* FILE BIOENG
- 1 FILE BIOSIS
- 0\* FILE BIOTECHABS
- 0\* FILE BIOTECHDS

55 FILES SEARCHED...

59 FILES SEARCHED...

- 0\* FILE ES BIOBASE
- 0\* FILE FOMAD
- 0\* FILE FOREGE
- 0\* FILE FROSTI
- 0\* FILE FSTA
- 1 FILE MEDLINE
- 0\* FILE NUTRACEUT
- 0\* FILE PHARMAML
- 2 FILE USPATFULL

88 FILES SEARCHED...

- 1 FILE USPAT2

9 FILES HAVE ONE OR MORE ANSWERS, 95 FILES SEARCHED IN STNINDEX

L1 QUE (RPKHP OR ARG PRO LYS HIS PRO) (P) (CASEIN OR S1 CASEIN?)

=> D rank

F1	2	USPATFULL
F2	1	AGRICOLA
F3	1	CABA
F4	1	CAPLUS
F5	1	SCISEARCH
F6	1	BIOSIS
F7	1	MEDLINE
F8	1	USPAT2
F9	1*	PASCAL

=> FIL F1-8

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.05	3.26

FILE 'USPATFULL' ENTERED AT 20:32:08 ON 13 FEB 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'AGRICOLA' ENTERED AT 20:32:08 ON 13 FEB 2006

FILE 'CABA' ENTERED AT 20:32:08 ON 13 FEB 2006  
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 20:32:08 ON 13 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 20:32:08 ON 13 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOSIS' ENTERED AT 20:32:08 ON 13 FEB 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 20:32:08 ON 13 FEB 2006

FILE 'USPAT2' ENTERED AT 20:32:08 ON 13 FEB 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s L1

L2	4	FILE USPATFULL
L3	1	FILE AGRICOLA
L4	1	FILE CABA
L5	1	FILE CAPLUS
L6	1	FILE SCISEARCH
L7	1	FILE BIOSIS
L8	1	FILE MEDLINE
L9	1	FILE USPAT2

TOTAL FOR ALL FILES

L10 11 L1

=> Dup rem L10

PROCESSING COMPLETED FOR L10

L11 5 DUP REM L10 (6 DUPLICATES REMOVED)

=> D L11 1-5 ibib abs

L11 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:189388 USPATFULL

TITLE: Molecular scaffolds for kinase ligand development

INVENTOR(S): Artis, Dean R., Kensington, CA, UNITED STATES  
Bremer, Ryan E., Oakland, CA, UNITED STATES

Gillette, Samuel J., Oakland, CA, UNITED STATES  
Hurt, Clarence R., San Ramon, CA, UNITED STATES  
Ibrahim, Prabha L., Mountain View, CA, UNITED STATES  
Zuckerman, Rebecca L., Alameda, CA, UNITED STATES  
Plexxikon, Inc. (U.S. corporation)

PATENT ASSIGNEE(S) :

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005164300	A1	20050728
APPLICATION INFO.:	US 2004-941635	A1	20040915 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-503277P	20030915 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278, US	
NUMBER OF CLAIMS:	74	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	19944	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Molecular scaffolds for compounds active on protein kinases are described, along with methods for using such scaffolds for kinase ligand development. The use of kinase structural information, exemplified with PIM-1 crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate particular kinases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2005:81466 USPATFULL  
TITLE: DNA polymerase compositions for quantitative PCR and methods thereof  
INVENTOR(S): Sorge, Joseph A., Wilson, WY, UNITED STATES  
Mueller, Reinhold Dietrich, San Diego, CA, UNITED STATES  
Padmabandu, Gothami, San Diego, CA, UNITED STATES  
Roelofs, Nick, San Diego, CA, UNITED STATES  
Hogrefe, Holly H., San Diego, CA, UNITED STATES  
PATENT ASSIGNEE(S): Stratagene (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005069908	A1	20050331
APPLICATION INFO.:	US 2003-734563	A1	20031212 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-408601, filed on 7 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2002-298680, filed on 18 Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-280962, filed on 25 Oct 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS / STR, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	62 Drawing Page(s)		
LINE COUNT:	7978		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the generation and characterization of Archaeal DNA polymerase mutants with deficient 3'-5' exonuclease activity and reduced base analog detection activity. The invention further provides for Archaeal DNA polymerase mutants with deficient 3'-5' exonuclease activity and reduced base analog detection activity containing additional mutations that modulate other DNA polymerase activities including DNA polymerization or reverse transcriptase activity. The

invention also discloses methods and applications of DNA polymerases with deficient 3'-5' exonuclease activity and reduced base analog detection activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 5 USPATFULL on STN DUPLICATE 1  
ACCESSION NUMBER: 2002:332607 USPATFULL  
TITLE: Phenylalanine-free protein and DNA coding therefor  
INVENTOR(S): Carr, Noel Gordon, Warwickshire, UNITED KINGDOM  
Mann, Nicholas Harold, Warwickshire, UNITED KINGDOM  
PATENT ASSIGNEE(S): Pharming Holding N. V., NETHERLANDS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495344	B1	20021217
	US 2002192744	A1	20021219
	WO 9428126		19941208
APPLICATION INFO.:	US 1996-545573		19960116 (8)
	WO 1994-GB1046		19940516
			19960116 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-10472	19930520
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Carlson, Karen Cochrane	
ASSISTANT EXAMINER:	Mitra, Rita	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Figure(s); 23 Drawing Page(s)	
LINE COUNT:	1376	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A DNA molecule coding for a food protein, such as ovalbumin or casein, modified so that the codons for phenylalanine have been omitted or replaced by codons for one or more other metabolisable amino acids. Also a modified edible protein coded for by such a DNA molecule. Such modified proteins are useful in the nutrition of patients suffering from phenylketonuria.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 5 USPATFULL on STN  
ACCESSION NUMBER: 2002:266265 USPATFULL  
TITLE: Casein derived peptides and uses thereof in therapy  
INVENTOR(S): Sidelman, Zvi, Tel Aviv, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002147144	A1	20021010
APPLICATION INFO.:	US 2001-942121	A1	20010830 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-IL100198, filed on 1 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	IL 2000-134830	20000301
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	G.E. EHRLICH (1995) LTD., c/o ANTHONY CASTORINA, SUITE 207, 2001 JEFFERSON DAVIS HIGHWAY, ARLINGTON, VA, 22202	
NUMBER OF CLAIMS:	283	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	3996	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the  $\alpha$ S1 fraction of milk casein. These peptides are capable of stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, hypercholesterolemia, hematological disorders and viral-related diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 5 AGRICOLA Compiled and distributed by the National Agricultural Library of the Department of Agriculture of the United States of America. It contains copyrighted materials. All rights reserved.  
(2006) on STN DUPLICATE 2

ACCESSION NUMBER: 2001:61956 AGRICOLA  
DOCUMENT NUMBER: IND23218252  
TITLE: Isolation and structural analysis of antihypertensive peptides that exist naturally in Gouda cheese.  
AUTHOR(S): Saito, T.; Nakamura, T.; Kitazawa, H.; Kawai, Y.; Itoh, T.  
SOURCE: Journal of dairy science, July 2000. Vol. 83, No. 7. p. 1434-1440  
Publisher: Savoy, Ill. : American Dairy Science Association.  
CODEN: JDSCAE; ISSN: 0022-0302  
NOTE: Includes references  
PUB. COUNTRY: Illinois; United States  
DOCUMENT TYPE: Article  
FILE SEGMENT: U.S. Imprints not USDA, Experiment or Extension  
LANGUAGE: English

AB Seven kinds of ripened cheeses (8-mo-aged and 24-mo-aged Gouda, Emmentaler, Blue, Camembert, Edam, and Havarti) were homogenized with distilled water, and water-soluble peptides were prepared by C-18 hydrophobic chromatography. The inhibitory activity to angiotensin I-converting enzyme and decrease in the systolic blood pressure in spontaneously hypertensive rats were measured before and after oral administration of each peptide sample. The strongest depressive effect in the systolic blood pressure (-24.7 mm Hg) and intensive inhibitory activity to angiotensin I-converting enzyme (75.7%) were detected in the peptides from 8-mo-aged Gouda cheese. Four peptides were isolated by HPLC with reverse-phase and gel filtration modes. Their chemical structures and origins, clarified by combination analyses of protein sequencing, amino acid composition, and mass spectrometry, were as follows: peptide A, **Arg-Pro-Lys-His-Pro-Ile-Lys-His-Gln** [ $\alpha$ (s1)-casein (CN), B-8P; f 1-9]; peptide B, **Arg-Pro-Lys-His-Pro-Ile-Lys-His-Gln-Gly-Leu-Pro-Gln** ( $\alpha$ (s1)-CN, B-8P; f 1-13); peptide F, **Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn** (beta-CN, A2-5P; f 60-68); and peptide G, **Met-Pro-Phe-Pro-Lys-Tyr-Pro-Val-Gln-Pro-Phe** (beta-CN, A2-5P; f 109-119). Peptides A and F, which were chemically synthesized, showed potent angiotensin I-converting enzyme inhibitory activity with little antihypertensive effects.

=>



# WEST Search History

Hide Items

Restore

Clear

Cancel

DATE: Monday, February 13, 2006

Hide?	Set Name	Query	Hit Count
		<i>DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L2	(rpkh   ARg Pro Lys his Pro) same casein	0
<input type="checkbox"/>	L1	(rpkh   ARg Pro Lys his Pro)	2

END OF SEARCH HISTORY